Last reviewed · How we verify

NCT04604210

Symptom-specific TMS Targets for Depression and Anxiety

Completed Phase 2 Last updated 1 August 2024
What this trial tests

Phase 2 trial testing Transcranial magnetic stimulation in Depression in 40 participants. Completed in 28 December 2023.

Timeline
3 February 2021
Primary endpoint
28 December 2023
28 December 2023

Quick facts

Lead sponsorBrigham and Women's Hospital
PhasePhase 2
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposetreatment
Enrollment40
Start date3 February 2021
Primary completion28 December 2023
Estimated completion28 December 2023
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Brigham and Women's Hospital

Who can join

Adults 18 to 65, any sex, with Depression or Anxiety. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This pilot study aims to compare two different treatment targets for transcranial magnetic stimulation, an FDA-approved treatment for major depressive disorder (MDD), in terms of their relative efficacy for depression versus anxiety.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

  1. A randomized trial comparing beam F3 and 5.5 cm targeting in rTMS treatment of depression demonstrates similar effectiveness.
    Trapp NT, Pace BD, Neisewander B, Ten Eyck P, et al · · 2023 · cited 31× · PMID 37714408 · DOI 10.1016/j.brs.2023.09.006
  2. Circuit-targeted modulation of anxiety symptoms in individuals with major depression: A randomized head-to-head TMS trial.
    Taylor JJ, Li J, Lin C, Jones E, et al · · 2026 · PMID 41912790 · DOI 10.1038/s41380-026-03535-1

Verify or expand the search:

Other trials of Transcranial magnetic stimulation

Trials testing the same drug.

Other recruiting trials for Depression

Currently open trials in the same condition.

Other Brigham and Women's Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04604210.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing